Transcranial Direct Current Stimulation Therapy for Bipolar Depression

Sponsor
University of East London (Other)
Overall Status
Recruiting
CT.gov ID
NCT05436613
Collaborator
University College, London (Other), King's College London (Other), Technische Universität Dresden (Other)
68
1
1
12
5.7

Study Details

Study Description

Brief Summary

Bipolar disorder is a severe and disabling disorder. The course of illness is often progressive but is highly heterogeneous between individuals and within the lifetime for an individual. The most common treatments are medications. However, for many individuals, combinations of medications are often required, and full recovery is infrequent.

The novel brain stimulation treatment, transcranial direct current stimulation (tDCS), is a potential first-line treatment for bipolar depression. The present research question is whether tDCS can be provided as a home-based treatment for bipolar depression for adults with bipolar disorder.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcranial Direct Current Stimulation
N/A

Detailed Description

The novel brain stimulation treatment, transcranial direct current stimulation (tDCS), is a potential first-line treatment for bipolar disorder. tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a headband worn over the forehead with two electrodes, which are small metal discs, where the current comes from. tDCS does not directly stimulate brain cells to cause a seizure like electroconvulsive therapy (ECT) and it does not induce brain cells to discharge like transcranial magnetic stimulation (TMS).

Clinical studies have shown that tDCS treatment could help to improve the symptoms of depression. The main side effects have been redness, skin irritation or sensations (itching, tingling or burning) under the electrodes. Less commonly reported side effects include headache or tiredness. tDCS is a portable and safe treatment.

The studies to date have mostly looked at tDCS treatment which has been provided in a research setting. This is a problem because the treatment requires daily sessions for several weeks which could limit whether individuals would be able to go every day. As tDCS is a portable and safe treatment, it could be provided in the community.

The present study is a proof-of-concept trial to assess the efficacy, acceptability and safety of tDCS treatment for bipolar depression within a community-based setting.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
68 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Community-based Transcranial Direct Current Stimulation Treatment for Bipolar Depression
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Device: transcranial direct current stimulation

6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.

Device: Transcranial Direct Current Stimulation
tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.

Outcome Measures

Primary Outcome Measures

  1. Clinical response [ Time Frame: At 6 weeks following course of tDCS treatment ] [6 weeks]

    As measured by clinician-rated MADRS score improvement of >= 50% following the course of tDCS treatment

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • diagnosis of bipolar disorder based on DSM-5 criteria

  • minimum score of 18 on the MADRS

  • being on a stable dosage of mood stabilizing medication for a minimum of two weeks

Exclusion Criteria:
  • comorbid psychiatric disorder

  • significant risk of suicide or self harm

  • any contraindications to tDCS, including implanted electronic medical devices

  • history of epilepsy

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of East London London United Kingdom E16 2RD

Sponsors and Collaborators

  • University of East London
  • University College, London
  • King's College London
  • Technische Universität Dresden

Investigators

  • Principal Investigator: Cynthia Fu, MD, PhD, University of East London

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Cynthia Fu, College Professor of Affective Neuroscience, University of East London
ClinicalTrials.gov Identifier:
NCT05436613
Other Study ID Numbers:
  • 308690
First Posted:
Jun 29, 2022
Last Update Posted:
Jun 29, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 29, 2022